Description
GLISOT-M1 FORTE Tablet (Bilayered) contains Glimepiride 1mg + Metformin 1000mg (Sustained Release), a combination of two oral antidiabetic medicines used to help manage blood glucose levels in adults with type 2 diabetes mellitus when prescribed by a qualified healthcare professional. Glimepiride belongs to the sulfonylurea class, while Metformin is a biguanide. Treatment should be supported by appropriate dietary measures, physical activity and regular glucose monitoring.
This combination brings together complementary mechanisms for glycaemic management. The sustained-release component is intended to release Metformin over an extended period; the exact release characteristics and administration instructions must be confirmed against the approved product information. Treatment suitability depends on the patient’s glucose levels, kidney function, medical history and other medicines.
CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business enquiries. Businesses researching a Glimepiride 1mg + Metformin 1000mg sustained-release Tablets manufacturer India should verify product availability, manufacturing details, approved specifications and relevant quality documentation directly with the company.
For procurement teams comparing a Glimepiride 1mg + Metformin 1000mg sustained-release Tablets manufacturer and supplier India, key checks include composition accuracy, product authorization, packaging details, batch traceability, shelf life and applicable commercial terms.
2. Key Ingredient
Composition:
Glimepiride 1mg + Metformin 1000mg
Glimepiride 1 mg: Glimepiride is a sulfonylurea antidiabetic medicine. It stimulates insulin release from pancreatic beta cells, helping lower blood glucose. Its use requires attention to hypoglycaemia, particularly if meals are delayed or skipped.
Metformin 1000 mg (Sustained Release): Metformin belongs to the biguanide class. It primarily reduces glucose production by the liver and improves the body’s sensitivity to insulin. The sustained-release formulation is designed to release the medicine over time according to its formulation characteristics.
For businesses researching a Glimepiride 1mg + Metformin 1000mg sustained-release pharmaceutical company India, procurement evaluation should include confirmation of the formulation, approved labelling, regulatory status and applicable quality systems.
Companies looking for a Glimepiride 1mg + Metformin 1000mg sustained-release medicine manufacturer India should confirm the actual manufacturing source, product authorization, batch documentation and relevant compliance records before entering into a commercial arrangement.
3. Key Benefits
Blood glucose management: The combination may help improve glycaemic control in eligible adults with type 2 diabetes when prescribed appropriately.
Complementary mechanisms: Glimepiride supports insulin release, while Metformin reduces hepatic glucose production and improves insulin sensitivity.
Sustained-release formulation: The Metformin component is designed for extended release, according to the approved product formulation.
Oral dosage form: Provides a Tablet-based treatment option for patients prescribed this combination.
Individualized treatment support: May be considered when a clinician determines that both active ingredients are appropriate for a patient’s treatment plan.
Structured diabetes care: Can form part of a broader management plan that includes dietary changes, physical activity and glucose monitoring.
Clinical suitability and response vary by patient. The combination is not appropriate for everyone, and Glimepiride can increase the risk of low blood glucose.
Pharmaceutical buyers searching for a Glimepiride 1mg + Metformin 1000mg sustained-release supplier India should verify availability, product authenticity, batch information, shelf life and storage requirements.
A Glimepiride 1mg + Metformin 1000mg sustained-release Tablet wholesaler and distributor India enquiry may involve stock availability, order quantities, supply arrangements, applicable licensing requirements and commercial terms.
Businesses evaluating a Glimepiride 1mg + Metformin 1000mg sustained-release bulk supplier India should request current product specifications, packaging details, batch traceability and relevant quality documentation before procurement.
A Glimepiride 1mg + Metformin 1000mg sustained-release pharmaceutical distributor India should confirm the product’s availability, distribution eligibility and approved product information before beginning commercial activities.
4. How Does It Work?
The two active ingredients work through different but complementary mechanisms.
Glimepiride stimulates pancreatic beta cells to release insulin by acting on sulfonylurea receptors and influencing ATP-sensitive potassium channels. The resulting insulin release can lower blood glucose, but it may also cause hypoglycaemia.
Metformin primarily decreases glucose production in the liver and improves insulin sensitivity in peripheral tissues. It helps the body use insulin more effectively and supports blood glucose regulation.
Together, these mechanisms can help manage blood glucose in selected adults with type 2 diabetes. The combination requires appropriate patient selection, regular monitoring and medical supervision. The sustained-release description refers to the Metformin formulation and should be checked against the approved product label.
5. Directions for Use
Dosage: Use only as prescribed by a qualified doctor. The appropriate regimen depends on the patient’s glucose control, kidney function, medical history and current medicines.
Administration: Follow the approved product label and the prescriber’s instructions regarding meals and timing.
Sustained-release Tablet: Do not crush, chew or split the Tablet unless the approved product information specifically permits it.
Regular timing: Take the medicine consistently according to the prescribed schedule. Do not adjust the dose independently.
Meals and hypoglycaemia: Because Glimepiride can cause low blood glucose, follow the prescriber’s instructions about meals and avoid skipping meals.
Monitoring: Check blood glucose as advised and attend recommended follow-up appointments, including kidney-function assessments.
Missed dose: Follow the advice of the doctor or pharmacist. Do not take an extra dose to compensate for a missed dose.
Lifestyle measures: Continue the recommended meal plan, physical activity and other diabetes-care measures.
This combination should not be started, stopped or adjusted without medical advice.
6. Possible Side Effects
Possible side effects associated with Glimepiride and Metformin include:
Hypoglycaemia: Low blood glucose may cause sweating, shaking, hunger, dizziness, confusion or palpitations. Severe episodes can be dangerous and require urgent treatment.
Gastrointestinal symptoms: Nausea, diarrhoea, abdominal discomfort, bloating or reduced appetite may occur, particularly with Metformin.
Headache or dizziness: These symptoms may occur in some patients and should be assessed if persistent.
Taste changes: A metallic taste may occur with Metformin.
Vitamin B12 reduction: Long-term Metformin use may lower vitamin B12 levels in some patients.
Weight changes: Changes may occur during diabetes treatment and should be discussed with a healthcare professional if concerning.
Important warning: Metformin is rarely associated with lactic acidosis, a serious condition requiring emergency medical assessment. Warning symptoms may include unusual muscle pain, marked weakness, breathing difficulty, unusual sleepiness or abdominal discomfort accompanied by feeling very unwell.
This list is not exhaustive. Patients should seek medical advice about persistent symptoms and urgent care for severe hypoglycaemia, suspected lactic acidosis or a serious allergic reaction.
7. Safety Information
Medical supervision: Use only under the guidance of a qualified healthcare professional.
Allergies: Do not use if there is a known serious allergy to either active ingredient or any component of the formulation.
Kidney function: Metformin is unsuitable in severe renal impairment. Kidney function should be assessed before treatment and monitored as clinically indicated.
Liver conditions: Significant liver disease may increase treatment risks and requires clinical assessment.
Heart failure and acute illness: Conditions involving reduced oxygen delivery, severe infection, dehydration or acute illness may increase the risk of Metformin-associated complications. Seek medical advice if seriously unwell.
Hypoglycaemia risk: Glimepiride can cause low blood glucose, especially with missed meals, fasting, strenuous activity, alcohol or certain interacting medicines.
Pregnancy and breastfeeding: Consult a doctor before use when pregnant, planning pregnancy or breastfeeding. The clinician should assess the most suitable diabetes treatment.
Alcohol: Avoid excessive alcohol and discuss alcohol use with the prescribing clinician because it can increase certain treatment risks.
Drug interactions: Inform the doctor about all prescription medicines, non-prescription medicines and supplements, particularly other glucose-lowering treatments.
Before procedures or contrast imaging: Tell the treating team that Metformin is being used. Temporary interruption may be required in certain situations depending on kidney function and the procedure.
Vitamin B12: Long-term treatment may warrant assessment for vitamin B12 deficiency when clinically indicated.
Storage: Store in the original packaging according to the approved product label, away from excessive heat and moisture, and out of children’s reach.
This information is educational and does not replace the approved prescribing information or individualized medical advice.
8. B2B Pharmaceutical Business Enquiries
CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business enquiries. Pharmaceutical buyers, wholesalers, distributors and eligible business partners can contact the company to confirm current product availability, specifications and applicable commercial arrangements.
Businesses searching for a Glimepiride 1mg + Metformin 1000mg sustained-release PCD pharma franchise India opportunity should enquire about eligible products, territory availability, partner requirements and commercial terms. Availability of a specific formulation or programme must be confirmed directly.
For a Glimepiride 1mg + Metformin 1000mg sustained-release Tablets PCD pharma franchise enquiry, prospective partners may request product details, relevant documentation, order requirements and applicable distribution conditions.
Companies considering a Glimepiride 1mg + Metformin 1000mg sustained-release Tablet PCD franchise should verify current programme eligibility and product availability before making investment or promotional commitments.
Businesses researching Glimepiride 1mg + Metformin 1000mg sustained-release third party manufacturing India should first confirm whether the proposed company offers such arrangements. Important checks include manufacturing permissions, product authorization, applicable GMP compliance, minimum batch quantities and quality documentation.
A Glimepiride 1mg + Metformin 1000mg sustained-release Tablet third party manufacturer India enquiry should cover the manufacturing facility’s regulatory status, quality systems, batch-release procedures, formulation specifications, packaging requirements and contractual responsibilities.
Companies exploring Glimepiride 1mg + Metformin 1000mg sustained-release contract manufacturing India should confirm service availability and discuss technical documentation, manufacturing authorization, quality agreements, regulatory responsibilities and commercial feasibility with the proposed manufacturing partner.
Visit the official CardianCare website to enquire about product information and applicable pharmaceutical business arrangements. Distribution, PCD franchise and manufacturing services should not be assumed to be available unless confirmed directly by the company.
9. For More Information
For more information about GLISOT-M1 FORTE Tablet (Bilayered) – Glimepiride 1mg + Metformin 1000mg Sustained Release, click here












Reviews
There are no reviews yet.